Recent Articles from GlobeNewswire

Company executives will discuss their business strategies, provide updates on recent developments, and answer questions live at VirtualInvestorConferences.com

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- 01 Quantum Inc. (“01 Quantum” or the “Company”) (TSX-V: ONE; OTCQB: OONEF), one of the first-to-market, enterprise level cybersecurity providers for the quantum computing era, announces that CEO Andrew Cheung will present live at the AI & Tech Virtual Investor Conference hosted by VirtualInvestorConferences.com, on April 23rd, 2026.

AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: For decades, GPS has operated as the invisible infrastructure underpinning modern warfare, enabling everything from precision-guided munitions to autonomous drone navigation. That assumption of reliability is now disappearing in real time. Across active conflict zones, satellite navigation signals are being jammed, spoofed and degraded at scale, turning one of the most trusted systems in defense into one of its most vulnerable. The consequences are immediate and measurable: Drones lose positioning, missions fail mid-operation and entire systems become ineffective in contested environments. As electronic warfare capabilities advance, GPS is increasingly becoming the first system adversaries attempt to disable, forcing a rapid reassessment of how modern platforms operate without it. In response, defense organizations worldwide are accelerating the search for alternatives that can function independently of satellite signals.

AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), are keenly aware of this evolution and are leveraging their expertise as pioneers in this space. Through its diversified pipeline and strategic holdings, including a 45% ownership stake in GMP Bio, which was recently measured at more than $1 billion enterprise value, the company exemplifies how advancing science can directly influence financial positioning. As the biotech sector increasingly aligns valuation with progress rather than revenue alone, Oncotelic provides a case study in how innovation is becoming a recognized asset class. Oncotelic joins an elite group of other key companies focused on advanced biotech platforms that target disease at the genetic or molecular level, including Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Denali Therapeutics Inc. (NASDAQ: DNLI). 

Wolo targeting approximately $5 million in revenue and $1 million in EBITDA by fiscal year 2027

Translational study in metastatic triple-negative breast cancer (mTNBC) shows leronlimab-mediated CCR5 inhibition induces PD-L1 expression, modulates immune checkpoint signaling, and is associated with long-term survival in heavily pretreated patients

SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif.

WEST PALM BEACH, Fla. and TOKYO, April 20, 2026 (GLOBE NEWSWIRE) -- Anthony, Linder & Cacomanolis, PLLC (“ALC”), a premier international capital markets and U.S. securities law firm, provides a strategic analysis of the March 12, 2026, Nasdaq Global Select Market debut of PayPay Corporation (Nasdaq: PAYP). The firm identifies the transaction as a seminal event for the Japanese "super-app" ecosystem and a repeatable structural blueprint for navigating the U.S. markets through the strategic alignment of Japanese domestic technology with U.S. institutional valuation expectations.

Contract modernizes and sustains the technology and infrastructure of Aircraft Armament Equipment (AAE), Support Equipment (SE), and Aerial Refueling System (ARS) integration for the MQ-25, building on SAIC’s 20-year partnership with the U.S. Navy

Strengthened Operations, Reinforced Retail Partnerships, and New Capital Position the Iconic Beauty House for Long-Term Success

A week-long Earth Day promotion gives homeowners a timely opportunity to upgrade before summer watering season

Fayetteville, Georgia, April 20, 2026 (GLOBE NEWSWIRE) -- Camp Southern Ground founder Zac Brown and the organization’s Board of Directors today announced a leadership transition, naming Michael (“Mike”) Caimona as the nonprofit’s next Chief Executive Officer. Caimona is expected to begin in May 2026, succeeding longtime CEO Mike Dobbs, retiring after a decade of leadership.

Partnership enables the integration of Turbo Energy’s AI-driven software into battery storage systems, supporting expansion of its high-margin international C&I pipeline

Company Advances Next-generation Patented MDMA Toward Patient Dosing in 2026

NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today welcomed the White House Executive Order aimed at accelerating research, regulatory pathways, and patient access to psychedelic treatments.

Howard’s nationwide reach across healthcare and public sector markets expands Nanox’s U.S. channel partner network to additional customer segments

Full year revenue grew 39.3% year over year to US$57.2 million, with second half revenue of US$31.5 million

MONTEVIDEO, Uruguay, April 20, 2026 (GLOBE NEWSWIRE) -- DLocal Limited (NASDAQ: DLO, “dLocal” or the “Company”), a leading cross-border financial infrastructure platform connecting global merchants to emerging markets, today announced that the Supreme Court of the State of New York, Appellate Division, First Department, has unanimously affirmed the dismissal of the putative class action lawsuit captioned In the Matter of DLocal Securities Litigation, Index No. 151778/23 (the “New York State Action”). The Supreme Court, New York County had previously granted the defendants’ motion to dismiss the complaint in its entirety, and the Appellate Division has now unanimously upheld that decision.

Company Has Repurchased 400,000 Common Shares in Open Market Transactions

MILWAUKEE, April 20, 2026 (GLOBE NEWSWIRE) -- Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, will announce its first quarter financial results before the market opens on Tuesday, May 5, 2026. The company will discuss its results in a live webcast at 7 a.m. CT (8 a.m. ET) on May 5, 2026. The webcast, along with supplemental financial information, can be accessed on the investor relations section of the Fiserv website at investors.fiserv.com. A replay will be available approximately one hour after the conclusion of the live webcast.

Advanced commercialization in the US, signing multiple new customer and distribution agreements for Nanox.ARC and accelerated activities around Nanox.AI

SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California on April 19, 2026. The Company demonstrated new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment (“TME”). The poster is available here.

CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2026 financial results will be released on Monday, April 27, 2026, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Single-family homes in the Lone Tree community coming to Davis County

Purpose-built for the neocloud era: a unified view of Axe Compute's NASDAQ equity and its Strategic Compute Reserve (SCR), the operational reserve that funds enterprise access to 435,000+ GPUs across 200+ global locations

ORLANDO, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. ("Abacus" or the "Company") (NYSE: ABX), a leader in the alternative asset management industry, today announced that it will participate in the 2026 Milken Institute Global Conference, taking place May 3–6, 2026 at The Beverly Hilton and Waldorf Astoria Beverly Hills in Beverly Hills, CA. The announcement marks the Company's first appearance at the annual gathering, which convenes thousands of leaders from across finance, business, government, health and philanthropy.

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- (Feature Impact) Three-row SUVs continue to evolve as drivers look for vehicles that balance everyday practicality with comfort, technology and capability. Automakers are responding with models designed to support family life, long road trips and outdoor travel.

Black Creek, GA, April 20, 2026 (GLOBE NEWSWIRE) -- Today, The Double D Foundation announced a significant financial commitment from Patriot Mobile, America’s only Christian conservative wireless provider. The announcement was made at the NRA Annual Meetings & Exhibits in Houston, Texas, underscoring the national significance of this investment and Patriot Mobile’s continued leadership in defending constitutional freedoms.

BRIDGEWATER, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the 2026 American Academy of Neurology (AAN).

SHENZHEN, China, April 20, 2026 (GLOBE NEWSWIRE) -- ZJK Industrial Co., Ltd. (NASDAQ: ZJK) (“ZJK Industrial”, “ZJK” or the “Company”), a high-tech precision parts and hardware manufacturer serving artificial intelligence (AI) infrastructure, consumer electronics, electric vehicles, aerospace, and other smart technologies, today announced that it is advancing a localized operational model for its Vietnamese subsidiary as part of its ongoing global operations planning to support a more balanced and sustainable global production network.

Offering Partners a New Recurring-Revenue Opportunity — Exclusive Preview at Directions North America

Net Interest Margin Expands on Disciplined Funding Strategy

Patient screening to begin this month

This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.

WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W. Ettenberg, a seasoned leader with more than 25 years of legal experience in the biopharmaceutical industry, as Chief Legal Officer (CLO). She will oversee Ardelyx’s legal, compliance, regulatory, and government affairs operations. Ms. Ettenberg succeeds Elizabeth Grammer, who has chosen to retire after an extraordinary 16-year career at the company.

Second candidate from Tenvie’s product engine to enter clinical development

MHRA submission follows EMA validation of the VIZZ MAA in March 2026

Outdoor retailer replaces legacy system with modern, headless architecture to improve scalability, flexibility and customer experience

Berlin, Germany, and Durham, N.C., USA, April 20, 2026 (GLOBE NEWSWIRE) -- Not intended for UK Media

Ingelheim, Germany, and London, UK – Boehringer Ingelheim today announced the expansion of its global Computational Innovation footprint with the launch of a new center for AI and machine learning in King’s Cross, London, UK, part of the Knowledge Quarter ecosystem. As the company continues to innovate and expand its AI capabilities in pharmaceutical R&D, this significant investment recognizes the UK’s commitment to AI and the life sciences sector.

100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial 

FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, April 30, 2026, to report its first quarter 2026 financial results and provide a business update.

Joint ventures underpin up to $80 million in contracted value across key global trade corridors, marking a transition to early-stage deployment with one of Turkey’s leading distribution networks

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company’s strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company’s development strategy.

Tel Aviv, Israel, April 20, 2026 (GLOBE NEWSWIRE) -- Nexera Technologies Ltd (“Nexera” or the “Company”) (Nasdaq: NEXR, NEXRW) (formerly known as Jeffs’ Brands Ltd), a data-driven company operating on the Amazon Marketplace expanding into the global homeland security sector through advanced artificial intelligence (“AI”) – driven solutions, today announced that its wholly-owned subsidiary, KeepZone AI Inc. (“KeepZone”), has entered into a strategic white label agreement with a third-party technology provider for the development of KeepZone’s AI-powered voice communication decision support system (the “Agreement”).

CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma (“TJ Bio”) today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s exclusive rights to felzartamab in the Greater China Region. With this agreement, Biogen now owns exclusive worldwide rights to felzartamab, which is currently being evaluated in global Phase 3 clinical studies across multiple immune-mediated diseases.

James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children’s Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ET

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 first quarter earnings conference call on Monday, May 11, 2026 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that it has appointed Heather Thiltgen to the Company’s Board of Directors, effective April 20, 2026. Ms. Thiltgen currently serves as the President of Presbyterian Health Plan and previously served as President & CEO of WellSense Health Plan.

Net income of $1.3M in FY 2025 versus net loss of $10.3M in FY 2024

$100M bought deal financing with lead orders from EdgePoint and cornerstone investor Eric Sprott$105M Senior Secured Credit Facility with EdgePoint

Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, recently announced that CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD) has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial.

NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, is a featured speaker at the POLITICO Health Care Summit on Tuesday, April 21. During the session, Mr. Elia will frame the evolving landscape of viral disease prevention, including the role of monoclonal antibodies in keeping Americans healthy moving forward.

Proven healthcare growth leader to drive disciplined, profitable expansion and scale across Lumexa Imaging’s platform

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels 

VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- SPARC AI Inc. (the “Company”) (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) is pleased to announce it has signed a second Ukrainian drone manufacturer to its Overwatch platform, marking continued commercial momentum for the Company's GPS-denied navigation and precision targeting software.

CALGARY, Alberta, April 20, 2026 (GLOBE NEWSWIRE) -- TransAlta Corporation (TransAlta or the Company) (TSX: TA) (NYSE: TAC) is pleased to announce the appointment of Mike Politeski as Executive Vice President, Finance and Chief Financial Officer (EVP and CFO) and Grant Arnold as Executive Vice President, Growth and Chief Commercial Officer (EVP and CCO), effective May 1, 2026 and May 6, 2026, respectively. The appointments correspond with the transition of current EVP and CFO, Joel Hunter, to the role of President and Chief Executive Officer (CEO) effective April 30, 2026, following the retirement of current President and CEO, John Kousinioris.

New brand reflects years of expertise and a deepened commitment to the rare disease community

GHENT, Belgium, April 20, 2026 (GLOBE NEWSWIRE) -- Aikido Security today launched Aikido Endpoint, a lightweight security agent that protects developer devices against software supply chain attacks by inspecting and blocking risky packages, IDE extensions, browser plugins, and AI tools before they're ever installed.

WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP) welcomes the newly-signed Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS, signed by President Trump on April 18, 2026. In the Order, the President notes that, “It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America.”

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group” or the “Company”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, announced today that, in connection with its ongoing substantial issuer bid (the “SIB”) to purchase for cancellation up to C$200,000,000 in value of its common shares (the “Shares”), the Ontario Securities Commission (the “OSC”), as Altus Group’s principal regulator, has granted an exemptive relief order exempting Altus Group from complying with certain extension take up, proportionate take up and related disclosure requirements.

CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers 

SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet’s prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026.

SHENZHEN, China, April 20, 2026 (GLOBE NEWSWIRE) -- Bodor Laser has ranked No. 1 globally in sales of laser cutting machines (1,000W and above) for the seventh consecutive year, according to data released by Qianzhan Industry Research Institute in March 2026. In 2025, the company again exceeded 10,000 units in annual sales, remaining the only manufacturer to achieve this milestone for seven consecutive years.

ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presented data evaluating safety margins of administration of deucrictibant immediate-release (IR) capsule(s) in combination with deucrictibant extended-release (XR) tablet at the Consortium of Independent Immunology Clinics (CIIC) Spring 2026 Conference, which took place from April 17-19, 2026, in Arlington, TX.

SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies

CHANTILLY, Va., April 20, 2026 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that the company has been selected by the Los Angeles Department of Water & Power (LADWP) to provide demand response technology, integration, and services to help manage and optimize the operation of distributed energy sources within the electrical grid.

WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the pricing of its underwritten offering of 18,018,014 shares of its voting common stock (the “Common Stock”) at a price of $4.44 per share, and, in lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 shares of its Common Stock at a price of $4.4399 per pre-funded warrant, which represents the per share offering price for the Common Stock less the $0.0001 per share exercise price for each such pre-funded warrant. Before deducting the underwriting discounts and commissions and estimated offering expenses, the total gross proceeds to Prelude are approximately $90.0 million. The offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.

Purpose-built AI infrastructure connects proprietary data, orchestrates workflows, and compresses development timelines significantly

Korean Deep-Tech Startup Earns Global Recognition for Battery Manufacturing AI

The annual general meeting of Equinor ASA (OSE: EQNR, NYSE: EQNR) will be held Tuesday 12 May 2026 at 15:00 CEST.

Grandisson to Purchase 1,131,273 Five-Year Warrants with $100 Strike Price

Extension aims to reflect long-term alignment among core shareholders and is expected to mitigate potential near-term share supply dynamics

Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer 

Vitaquest outlines quality, packaging, and compliance systems supporting product quality and performance across dietary supplement manufacturing operations